### **Positivity in serum MMP-3 after clinical remission or low disease**

# 2 activity at 52 weeks leads to future joint destruction in patients

3

#### with rheumatoid arthritis

#### 4 Authors

- 5 Hiroe Konishi<sup>1</sup>, Mai Morimoto<sup>1</sup>, Kosaku Murakami<sup>2</sup>, Hideo Onizawa<sup>3</sup>, Akira Onishi<sup>3</sup>, Takayuki
- 6 Fujii<sup>3,4</sup>, Koichi Murata<sup>3,4</sup>, Masao Tanaka<sup>3</sup>, Akio Morinobu<sup>5</sup>, Masayoshi Nakano<sup>1</sup>, and Masahiro
- 7 Koshiba<sup>1,\*</sup>

#### 8 Affiliations

- 9<sup>1</sup> Department of Clinical Laboratory Medicine, Hyogo Medical University School of Medicine,
- 10 Hyogo, Japan
- <sup>11</sup> <sup>2</sup> Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer
- 12 Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto,

13 Japan

- <sup>14</sup> <sup>3</sup> Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine,
- 15 Kyoto University, Kyoto, Japan
- <sup>4</sup> Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto,

17 Japan

- <sup>18</sup> <sup>5</sup> Department of Rheumatology and Clinical Immunology, Graduate School of Medicine,
- 19 Kyoto University, Kyoto, Japan

#### 20 ORCID & Email:

- 21 Hiroe Konishi ID: https://orcid.org/0000-0003-4267-1665 Email hiroe-k@hyo-med.ac.jp
- 22 Mai Morimoto ID: https://orcid.org/0009-0005-3703-5922 Email mai-m@hyo-med.ac.jp
- 23 Masayoshi Nakano ID: https://orcid.org/0000-0003-0667-8093 Email ms-nakano@hyo-
- 24 med.ac.jp
- 25 Masahiro Koshiba ID: https://orcid.org/ 0000-0002-0839-1005 Email mkoshiba@hyo-
- 26 med.ac.jp
- 27 Kosaku Murakami ID: https://orcid.org/0000-0001-5981-4648 Email kosaku@kuhp.kyoto-
- 28 u.ac.jp
- 29 Hideo Onizawa ID: https://orcid.org/0009-0002-9372-726X Email honizawa@kuhp.kyoto-
- 30 u.ac.jp
- 31 Akira Onishi ID: https://orcid.org/0000-0002-3120-1273 Email aonishi@kuhp.kyoto-u.ac.jp
- 32 Takayuki Fujii ID: https://orcid.org/0000-0002-6556-1226 Email fujiit@kuhp.kyoto-u.ac.jp
- 33 Koichi Murata ID: https://orcid.org/0000-0002-7896-3937 Email kchm@kuhp.kyoto-u.ac.jp
- 34 Masao Tanaka ID: https://orcid.org/0000-0002-8942-2933 Email masatana@kuhp.kyoto-
- 35 u.ac.jp
- Akio Morinobu ID: https://orcid.org/0000-0002-4672-638X Email morinobu@kuhp.kyotou.ac.jp
- 38

#### 39 <sup>\*</sup>Corresponding author

- 40 Masahiro Koshiba
- 41 Email <u>mkoshiba@hyo-med.ac.jp</u>.
- 42 **Running title:** Serum MMP-3 Leads To Future Joint Destruction

43

44 **Statements and Declarations:** 

#### 45 **Competing Interests**

- 46 The Department of Advanced Medicine for Rheumatic Diseases in Kyoto University is
- 47 supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan, and five
- 48 pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd,
- 49 UCB Japan Co. Ltd, AYUMI Pharmaceutical Co., and Asahi Kasei Pharma Corp.). It is also
- 50 supported by a grant from Daiichi Sankyo Co. Ltd. The above-mentioned pharmaceutical
- 51 companies were not involved in the study design, data collection and analysis, manuscript
- 52 writing, or manuscript submission.
- 53 KMurakami received speaker fees and/or consulting fees from Eisai Co. Ltd., Chugai
- 54 Pharmaceutical Co. Ltd., Pfizer Inc., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma
- 55 Corporation, UCB Japan Co. Ltd., Daiichi Sankyo Co. Ltd., and Astellas Pharma Inc.
- 56 HO received research grants and/or speaker fees from AbbVie, Asahi Kasei, Astellas Pharma
- 57 Inc., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, and

58 Daiichi Sankyo Co. Ltd.

59 AO received research grants and/or speaker fees from Pfizer Inc., Bristol-Myers Squibb.,

- 60 Advantest, Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K. K.,
- 61 Ono Pharmaceutical Co., UCB Japan Co., Mitsubishi Tanabe Pharma Co., Eisai Co. Ltd.,
- 62 AbbVie Inc., Takeda Pharmaceutical Co. Ltd., and Daiichi Sankyo Co. Ltd.
- 63 TF received speaker fees from AbbVie, Asahi Kasei, Jansen, Tanabe Mitsubishi, and Eisai.
- 64 KMurata received speaker and/or consulting fees from AbbVie G.K., Eisai Co., Ltd., Pfizer Inc.,
- 65 Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Bristol-
- 66 Myers Squibb, Daiichi Sankyo Co. Ltd., and Asahi Kasei Pharma Corp.
- 67 MT received research grants and speaker fees from AbbVie G.K., Asahi Kasei Pharma
- 68 Corporation, Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd.,
- 69 Eisai Co., Ltd., Eli Lilly and Company, Pfizer Inc., UCB Japan Co., Ltd., Janssen Pharmaceutical
- 70 K.K., Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Taisho Pharma Co., Ltd.,
- 71 and Teijin Pharma, Ltd.
- 72 AM received honorarium from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan
- 73 K.K., Eisai Co. Ltd., Pfizer Inc., Bristol-Myers Squibb., Mitsubishi Tanabe Pharma Co., Astellas
- 74 Pharma Inc., and Gilead Sciences Japan.
- 75 AM received research grants from AbbVie G.K., Asahi Kasei Pharma Corp., Chugai
- Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., and Eisai Co. Ltd. for work outside
  the scope of this study.
- 78 HK, MM, MN, and MK declare no conflicts of interest.

#### 79 Funding

80 Open access funding provided by the Hyogo Medical University.

#### 81 Acknowledgements

- 82 The authors thank the patients and medical staff of both hospitals for their contribution to
- this study. We would like to extend our heartfelt gratitude to Haruo Horii, Naohiro Ito, and
- 84 Masatoshi Fujii for their generous financial support for the KURAMA cohort. The funders
- were not involved in the study design, data collection, analysis, interpretation of the data,
- 86 writing of the manuscript, or in any decision to publish the results. We also thank Enago
- 87 (www.enago.jp) for the English language review.

#### 88 Author contributions

- 89 HK, MM, and MK contributed to design, data acquisition and analysis, statistical calculations,
- and manuscript writing. KMurakami, HO, AO, TF, KMurata, MT, AM, and MN contributed to
- 91 the data analysis. All co-authors contributed substantially to the concept and revisions. They
- 92 approved the final version for submission.

## 94 Abstract

- 95 Introduction. This study aimed to evaluate whether a long-term increase in serum matrix
- 96 metalloproteinase-3 (MMP-3) levels leads to joint destruction in rheumatoid arthritis (RA)
- 97 patients with negative serum C-reactive protein (CRP) values after methotrexate (MTX)

98 therapy.

99 Methods. Patients with RA (n = 182) whose CRP values became negative due to MTX therapy

100 were divided into two groups based on their MMP-3 positivity at the end of the observation

101 period, and the 1-year progression of joint destruction was retrospectively compared.

102 Radiological joint destruction was assessed using the modified van der Heijde total sharp

103 score (mTSS).

- 104 **Results.** Among 109 (MMP-3(-), n = 63; MMP-3(+), n = 46) patients who achieved low
- 105 disease activity or clinical remission (28 joint disease activity score erythrocyte
- sedimentation rate < 2.6), joint destruction ( $\Delta mTSS \ge 0.5$ ) progressed in 24.6% and 48.9% of

107 the MMP-3(-) and MMP-3(+) groups (p < 0.01), respectively. Prednisolone-induced increases

108 in serum MMP-3 levels also resulted in joint destruction.

109 Conclusion. To prevent progressive joint destruction, the target MMP-3 value is 49.7 ng/mL

- in female patients, which is below the current MMP-3 cutoff value of 59.7 ng/mL. Residual
- 111 MMP-3 activity may lead to the progression of joint destruction in patients with RA, even

112 after CRP normalization by successful treatment with MTX.

113

114 Keywords: Rheumatoid arthritis, matrix metalloproteinase-3, C-reactive protein, modified

115 van der Heijde total sharp score, joint destruction

116

# 117 INTRODUCTION

118 Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovitis and joint destruction, which leads to disability [1]. According to current 119 recommendations, achieving clinical remission is the therapeutic target for patients with RA, 120 121 with low disease activity (LDA) considered the best possible alternative. A treat-to-target 122 strategy should be employed when treating patients with RA, and treatment decisions 123 should be based on disease activity and other patient factors, such as comorbidities and the 124 progression of structural damage [2, 3]. 125 Methotrexate (MTX) is recommended as the first-line drug for the initial treatment of RA [4, 5]. MTX remains the anchor drug in RA. MTX is not only an efficacious conventional 126 127 synthetic (cs) disease-modifying antirheumatic drug (DMARD) but is also the basis for combination therapies, either with prednisolone (PSL) or with other csDMARDs, biological 128 DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs) [6]. While serum CRP 129 130 values often become negative after MTX therapy, joint destruction can still progress in some cases [7]. 131

Matrix metalloproteinases (MMPs) are a family of enzymes that catalyze
 extracellular matrix degradation. Most MMPs are secreted as inactive preproteins that are

activated when cleaved by extracellular proteinases [8]. MMP-3 is a proteinase secreted by synovial fibroblasts and chondrocytes in joints. In RA, joint destruction can be accelerated by active MMP-3, and serum MMP-3 levels in RA have been well evaluated as an indicator of disease activity. In RA, the level of MMP-3 within the joints is markedly higher than that of other MMPs [9]. This high MMP-3 level is believed to mediate joint destruction in patients with RA [10, 11].

140 Increases in serum MMP-3 levels are observed from early to advanced stages in 80%–90% of patients with RA. Serum MMP-3 levels in patients with RA reflect the degree of 141 142 synovial proliferation and may serve as a prognostic indicator of disease progression, 143 particularly in early RA onset [12]. Elevated or increasing serum MMP-3 levels in patients 144 with RA are associated with the rapid progression of joint destruction. Conversely, serum MMP-3 levels decrease when the condition stabilizes in response to the therapeutic effect of 145 146 DMARDs, including bDMARDs [13]. There are sex differences in serum MMP-3 levels; the 147 upper limits of the reference range are 121.0 and 59.7 ng/mL for male and female 148 individuals, respectively. Researchers have reported that normal serum MMP-3 levels, in 149 combination with CRP levels or disease activity, are useful for predicting clinical remission 150 and normal physical function in patients with RA [14]. However, progression of joint 151 destruction is observed even in patients with RA with negative CRP values, disease activity in 152 remission, or LDA [15]. Therefore, we observed patients with RA with negative CRP values 153 during MTX monotherapy or combination therapy for 1 year and investigated whether 154 serum MMP-3 levels are correlated with joint destruction. Furthermore, in this study, we developed an ideal cutoff value for MMP-3 based on the relationship between blood MMP-3 155

156 levels and joint destruction.

157

### 158 **METHODS**

## 159 Study design and patient selection

160	The retrospective study enrolled patients who visited Hyogo Medical University
161	Hospital or Kyoto University Hospital between April 1, 2011 to April 30, 2021 and met the
162	1987 and/or 2010 RA classification criteria. Patients with RA (n = 182) whose CRP values
163	became negative following MTX monotherapy or DMARD combination therapy (MTX
164	together with other DMARDs) were divided into two groups based on their serum MMP-3
165	positivity at the end of the observation period, and the 1-year progression of joint
166	destruction was retrospectively compared through X-rays.

167

### 168 Assessment

The medical records of the patients, including information related to the visual analog scale (VAS), CRP, erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), serum MMP-3, anti-citrullinated protein antibody (ACPA), 28 joint disease activity score (DAS28), and clinical disease activity index (CDAI), were retrospectively reviewed by two authors (HK, MM). Patients who had moderate or severe renal dysfunction (eGFRcre < 45 mL/min/1.73 m<sup>2</sup>) or were taking oral PSL > 25 mg/day were excluded. After the observation period, the

175	patients were divided into the serum MMP-3 positive (MMP-3(+)) and MMP-3 negative
176	(MMP-3(-)) groups based on whether their serum MMP-3 levels were above or below the
177	upper reference limit for each sex. Progression was assessed via radiography of the hands,
178	wrists, and feet and scored chronologically using the mTSS method recommended by
179	Bruynesteyn et al. [16]. Radiographs of each patient's hands and feet were taken upon the
180	initiation of MTX therapy and 1 year after MTX therapy. Radiographic progression was
181	evaluated independently by two rheumatologists (MM and KMurakami), who were trained
182	and certified by Prof. van der Heijde (Leiden University) for the mTSS scoring system.
183	Moreover, mTSS progression after 1 year ( $\Delta$ mTSS) was calculated from the mean progression
184	determined by the two readers. If $\Delta mTSS$ differed by $\geq 10$ , the two rheumatologists discussed
185	and reached a consensus. Patients were classified as having structural remission ( $\Delta$ mTSS <
186	0.5) or radiographic evidence of progression ( $\Delta mTSS \ge 0.5$ ).

187

### 188 Ethical approval

The retrospective study protocol was approved by the Ethics Committee of Hyogo Medical University (Protocol No. 3923). This retrospective study waived the requirement for individual informed consent owing to the "opt-out" principle. Patients were allowed to "optout" of the database if they wished. Clinical data at Kyoto University were approved by the Medical Ethics Committee of the Kyoto University Graduate School and Faculty of Medicine (No. R0357), and written informed consent to participate in the study was obtained from all patients of Kyoto University Hospital.

# 196 Statistical analysis

197	All statistical analyses were performed using IBM SPSS Statistics version 29 (IBM
198	Corp., Armonk, NY, USA). Fisher's exact test was used for categorical variables. Receiver
199	operating characteristic (ROC) curve analysis was used to determine the cutoff value and p
200	values of <0.05 were considered statistically significant.

201

# 202 **RESULTS**

### 203 Clinical characteristics of patients upon the initiation of MTX

204 therapy

205	Of the patients who continued MTX monotherapy or DMARD combination therapy
206	for at least 1 year, 182 (including 142 females) could be evaluated radiographically. Upon
207	initiation of MTX therapy, participants had a mean age of 59.1 $\pm$ 12.1 years, with a mean
208	disease duration of 9.3 $\pm$ 10.1 years. Among them, 64.2% were RF-positive, 64.2% were
209	ACPA-positive, and 56.0% were both RF- and ACPA-positive. The mean DAS28-ESR was 2.46 $\pm$
210	0.98, the mean CDAI was 4.51 $\pm$ 5.48, the mean MTX dose was 7.0 $\pm$ 2.7 mg/week in 125
211	(68.7%) patients, and the mean PSL dose was 4.1 $\pm$ 2.6 mg/day in 76 patients (41.8%) (Table
212	1).

 213
 Table 1. Subject demographics and clinical characteristics at Oweek

 Parameter

Age (years)	59.1 ± 12.1
Female, n (%)	142 (78.0%)
RA duration (years)	9.3 ± 10.1
RF positive	64.2%
ACPA positive	64.2%
RF & ACPA positive	56.0%
DAS28 (ESR)	2.46 ± 0.98
CDAI	4.51 ± 5.48
MTX use at baseline, n (%)	125 (68.7)
MTX dose (mg/w)	7.0 ± 2.7
PSL use at baseline, n (%)	76 (41.8)
PSL dose (mg)	4.1 ± 2.6

214 Values are presented as mean ± standard deviation unless stated otherwise.

215 CCP, cyclic citrullinated peptide; MTX, methotrexate; RA, rheumatoid arthritis; RF,

216 rheumatoid factor; DAS28, Disease Activity Score 28-joint assessment; CDAI, Clinical Disease

217 Activity Index; PSL, prednisolone.

218

### 219 Comparison of the progression of joint damage estimated by

# radiography in the MMP-3(-) and MMP-3(+) groups

221	The progression rates of joint destruction in the MMP-3(-) (n = 100) and MMP-3(+)
222	groups (n = 82) were 22.5% (n = 23) and 42.1% (n = 35), respectively (p < 0.01). Changes in
223	the mTSS from baseline ( $\Delta$ mTSS) were 0.46 $\pm$ 1.12 and 0.97 $\pm$ 1.99 (p = 0.03) (Fig. 1A), and
224	the nonprogression rates ( $\Delta$ mTSS < 0.5) were 77.5% and 57.9%, respectively (Fig. 1B). At
225	baseline, the PSL usage rates were 26.0% (n = 26) and 61.0% (n = 50). The progression of
226	joint destruction was examined in 106 of these 182 patients (MMP-3(-), n = 74; MMP-3(+), n

227 = 32) who were PSL-free. Among these patients, the progression rates of joint destruction 228 were 23.6% (n = 18) and 48.4% (n = 16) in the MMP-3(-) and MMP-3(+) groups, respectively 229 (p = 0.01). The ΔmTSS values were  $0.53 \pm 1.24$  and  $1.16 \pm 1.98$  (p = 0.05) (Fig. 1C), and the 230 nonprogression rates were 76.4% and 51.6%, respectively (Fig. 1D).

231 Even when the CRP value becomes negative at 52 weeks, it does not necessarily indicate the absence of inflammation. We sometimes encounter patients with a few small 232 233 joint swellings and negative CRP values. Thus, we examined the progression of joint 234 destruction in 97 of these 182 patients with no swollen joints at 52 weeks (MMP-3(-), n = 58; MMP-3(+), n = 39). Among these patients, the progression rates of joint destruction 235 236 were 19.8% (n = 12) and 42.3% (n = 17) in the MMP-3(-) and MMP-3(+) groups, respectively 237 (p = 0.02). The  $\Delta mTSS$  values were 0.37 ± 0.89 and 1.18 ± 2.45 (p = 0.02) (Fig. 1E), and the 238 nonprogression rates were 80.2% and 57.7%, respectively (Fig. 1F). The PSL usage rates at 239 baseline were 27.6% (n = 16) and 53.8% (n = 21), respectively. We found no correlation 240 between CRP and MMP-3 in 182 patients (Fig. 1G); therefore, joint destruction progresses more likely in the MMP-3(+) group than in the MMP-3(-) group (Table 2). 241



cumulative probability plot of mTSS. (E) Patients with no swollen joints at 52 weeks (n = 97), change from baseline in the modified total sharp score ( $\Delta$ mTSS). (F) Patients with no swollen joints at 52 weeks (n = 97), cumulative probability plot of mTSS. (G) Correlations between CRP and MMP-3 values in 182 patients. Values in (A)(C)(E) indicate the mean (SD) at each time point and in the MMP-3(-) or MMP-3(+) group. Percentages in (B)(D)(F) indicate the progression rates of joint destruction ( $\Delta$ mTSS > 0.5) in the MMP-3(-) or MMP-3(+) group.

Parameter	MMP-3 (-)	MMP-3 (+)	<i>p</i> value
Age (years)	58.1 ± 11.4	62.5 ± 12.6	0.01
Female / Male	73/ 27	69 / 13	0.07
RA duration (years)	9.3 ± 10.3	11.6 ± 9.8	0.17
RF positive	52.6%	76.9%	< 0.01
ACPA positive	54.4%	75.0%	0.02
RF & ACPA positive	43.9%	69.2%	< 0.01
DAS28 (ESR)	2.29 ± 1.02	2.67 ± 0.9	0.03
CDAI	4.11 ± 6.20	4.98 ± 4.48	0.37
mTSS baseline (week 0)	27.6 ± 45.7	39.8 ± 52.8	0.1
Δ mTSS	0.46 ± 1.12	0.97 ± 1.99	0.03
0.5 ≦ ∆ baseline, n (%)	23 (23.0)	35 (42.7)	
progression ratio	22.5	42.1	< 0.01
Without PSL use at baseline, n	74	32	
Δ mTSS	0.53 ± 1.24	$1.16 \pm 1.98$	0.05
0.5 $≦$ ∆ baseline, n (%)	18 (24.3)	16 (50.0)	
progression ratio	23.6	48.4	0.01
no swollen joints group, n	58	39	
ΔmTSS	0.37 ± 0.89	$1.18 \pm 2.45$	0.02

#### Table 2. MMP-3 (-) group or MMP-3 (+) group analysis at 52weeks

0.5 $\leq$ $\Delta$ baseline, n (%)	12 (20.7)	17 (43.6)	
PSL use at baseline, n (%)	16 (27.6)	21 (53.8)	
progression ratio	19.8	42.3	0.02
CRP-negative group (week 0), n	79	63	
ΔmTSS	0.50 ± 1.20	1.16 ± 2.20	0.02
0.5 $\leq$ $\Delta$ baseline, n (%)	19 (24.1)	29 (46.0)	
PSL use at baseline, n (%)	19 (24.1)	36 (57.1)	
progression ratio	25.7	46.0	< 0.01
DAS-28 : LDA and the clinical remission group, n	63	46	
ΔmTSS	0.42 ± 1.02	$1.21 \pm 2.41$	0.02
0.5 $\leq$ $\Delta$ baseline, n (%)	16 (25.4)	23 (50.0)	
PSL use at baseline, n (%)	15 (23.8)	24 (52.2)	
progression ratio	25.4	50.0	< 0.01
DAS-28 : LDA and the clinical remission group, n (without PSL use at baseline)	48	22	
ΔmTSS	0.49 ± 1.15	1.39 ± 2.23	0.03
0.5 $\leq$ $\Delta$ baseline, n (%)	13 (27.1)	12 (54.5)	
progression ratio	27.1	54.5	0.03
CDAI : LDA and the clinical remission group, n	70	58	
ΔmTSS	0.36 ± 0.83	1.19 ± 2.23	< 0.01
0.5 $\leq$ $\Delta$ baseline, n (%)	17 (24.3)	28 (48.3)	
PSL use at baseline, n (%)	18 (25.7)	29 (50.0)	
progression ratio	23.6	47.4	< 0.01
CDAI : LDA and the clinical remission group, n (without PSL use at baseline)	52	29	
ΔmTSS	0.42 ± 0.93	1.19 ± 2.03	0.02
0.5 $\leq$ $\Delta$ baseline, n (%)	14 (26.9)	14 (48.3)	
progression ratio	26	46.6	0.08

255 Values are presented as mean ± standard deviation unless stated otherwise.

DAS28, Disease Activity Score 28-joint assessment; ESR, erythrocyte sedimentation rate;
 mTSS, modified Total Sharp Score; LDA, low Disease Activity; CDAI, Clinical Disease Activity
 Index; PSL, prednisolone.

259

### 260 Effect of PSL-induced elevation of serum MMP-3 on the progression

### 261 of joint destruction

262	In the MMP-3(+) group, progression of joint destruction was assessed in groups
263	with (n = 46) or without (n = 36) PSL. We evaluated whether the oral PSL-induced serum
264	MMP-3 increase was relevant to the joint destruction progression. However, progression of
265	joint destruction was observed in 43.1% (n = 16) and 40.2% (n = 19) of the patients in the
266	PSL (-) and PSL (+) groups (p = 0.82); $\Delta$ mTSS values were 1.03 ± 1.90 and 0.92 ± 2.08 (p =
267	0.82) (Fig. 2A); and the nonprogression rates were 56.9% and 59.7%, respectively (Fig. 2B).
268	We found no significant difference in disease activity between the two groups (Table 3).
269	These data suggest that the increase in serum MMP-3 levels induced by PSL is also involved
270	in the progression of joint destruction.
271	

Fig 2. For the MMP-3+ group (n = 83), progression of joint destruction was analyzed in the
PSL(-) and PSL(+) groups at 52 weeks. (A) Change from baseline in the modified total sharp
score (ΔmTSS). Values in indicate mean (SD) at each time point and in the PSL(-) or PSL(+)
group. (B) Cumulative probability plot of mTSS. Percentages indicate the progression rates of
joint destruction (ΔmTSS > 0.5) of each treatment group.

Parameter	PSL (-)	PSL (+)	<i>p</i> value
MMP-3 (+) group, n	36	46	
DAS28 (ESR)	2.49 ± 0.86	2.88 ± 1.02	0.11
CDAI	3.64 ± 3.23	5.73 ± 5.05	0.06
ΔmTSS	1.03 ± 1.90	0.92 ± 2.08	0.82
0.5 $\leq$ $\Delta$ baseline, n (%)	16 (44.4)	19 (43.6)	
progression ratio	43.1	40.2	0.82

#### 277 Table 3. In the MMP-3 (+) group, PSL (-) group or PSL (+) group analysis at 52weeks

278 Values are presented as mean ± standard deviation unless stated otherwise.

279 DAS28, Disease Activity Score 28-joint assessment; ESR, erythrocyte sedimentation rate;

280 mTSS, modified Total Sharp Score; CDAI, Clinical Disease Activity Index; PSL, prednisolone.

281

### 282 Comparison of the progression of joint damage estimated by

# radiography between the MMP-3(-) and MMP-3(+) subgroups

### within the CRP-negative group at baseline

285	We examined the progression of joint destruction in 142 of 183 patients with RA
286	(MMP-3(-), n = 79; MMP-3(+), n = 63) who were CRP negative at baseline. Progression of
287	joint destruction was found in 25.7% and 46.0% (p < 0.01); the $\Delta$ mTSS values were 0.50 $\pm$
288	1.20 and 1.16 $\pm$ 2.20 (p = 0.02) (Fig. 3A); and the nonprogression rates ( $\Delta$ mTSS < 0.5) were
289	74.3% and 54.0% (Fig. 3B. The PSL usage rates at baseline were 24.1% (n = 19) and 57.1% (n
290	= 36). This suggests that progression of joint destruction is likely if serum MMP-3 levels
291	remain positive, even when baseline CRP is negative (Table 2).

Fig 3. For the CRP-negative group at baseline (n = 142), progression of joint destruction
was analyzed in the MMP-3(-) and MMP-3(+) groups at 52 weeks. (A) Change from
baseline in the modified total sharp score (ΔmTSS). Values indicate mean (SD) at each time
point and MMP-3(-) or MMP-3(+) group. (B) Cumulative probability plot of mTSS.
Percentages indicate the progression rates of joint destruction (ΔmTSS > 0.5) of each
treatment group.

299

### 300 Comparison of the progression of joint damage estimated by

301	radiography in the MMP-3(–) and MMP-3(+) groups with LDA or
302	clinical remission (DAS28-ESR < 2.6 or CDAI $\leq$ 2.8).

303 Clinical remission is the therapeutic target for patients with RA, with LDA being the 304 best possible alternative. Thus, the study enrolled 109 of 183 patients with RA (MMP-3(-), n = 63; MMP-3(+), n = 46) who had achieved LDA or clinical remission (DAS28-ESR < 2.6). The 305 progression of joint destruction was found in 24.6% (MMP-3(-)) and 48.9% (MMP-3(+)) (p < p306 307 0.01); the  $\Delta$ mTSS values were 0.42 ± 1.02 and 1.21 ± 2.41 (p = 0.02) (Fig. 4A); and the nonprogression rates ( $\Delta$ mTSS < 0.5) were 75.4% and 51.1%, respectively (Fig. 4B). The 308 progression of joint destruction was further examined in 70 of these 109 patients (MMP-3(-), 309 310 n = 48; MMP-3(+), n = 22) who were PSL-free. Among these patients, progression of joint destruction was observed in 26.0% and 47.7% (p = 0.03), the  $\Delta$ mTSS values were 0.49 ± 1.15 311 and  $1.39 \pm 2.23$  (p = 0.03), and the nonprogression rates were 72.9% and 45.5%, respectively. 312

313	Similarly, 128 of 182 patients with RA (MMP-3( $-$ ), n = 70; MMP-3(+), n = 58) who had
314	achieved LDA or clinical remission (CDAI $\leq$ 2.8) were compared. The progression of joint
315	destruction was found in 23.6% (MMP-3(-)) and 47.4% (MMP-3(+)) (p < 0.01), the $\Delta$ mTSS
316	values were 0.36 $\pm$ 0.83 and 1.19 $\pm$ 2.23 (p < 0.01) (Fig. 4C), and the nonprogression rates
317	( $\Delta$ mTSS < 0.5) were 76.4% and 52.6%, respectively (Fig. 4D). We further examined the
318	progression of joint destruction in 81 of these 128 patients (MMP-3(-), n = 52; MMP-3(+), n
319	= 29) who were PSL-free. Among these patients, we observed progression of joint
320	destruction in 26.0% and 46.6% (p = 0.08); the $\Delta$ mTSS values were 0.42 ± 0.93 and 1.19 ±
321	2.03 (p = 0.02); and the nonprogression rates were 74.0% and 53.4%, respectively. Joint
322	destruction was more severe in the MMP-3(+) group than in the MMP-3(-) group (Table 2),
323	indicating that neither the achievement of LDA nor clinical remission is sufficient to prevent
324	the progression of joint destruction, particularly when the serum MMP-3 levels remain
325	positive.

326

327 Fig 4. For patients with rheumatoid arthritis in remission or with low disease activity, progression of joint destruction was analyzed in the MMP-3(-) and MMP-3(+) groups at 52 328 weeks. (A) Patients with rheumatoid arthritis in remission or with low disease activity on the 329 DAS28 (n = 109), change from baseline in the modified total sharp score ( $\Delta$ mTSS). (B) 330 331 Patients with rheumatoid arthritis in remission or with low disease activity on the DAS28 (n = 109), cumulative probability plot of mTSS. (C) Patients with rheumatoid arthritis in 332 remission or with low disease activity on the CDAI (n = 128), change from baseline in  $\Delta mTSS$ . 333 334 (D) Patients with rheumatoid arthritis in remission or with low disease activity on the CDAI 19

335 (n = 128), cumulative probability plot of mTSS. Values in (A)(C) indicate mean (SD) at each time point and in the MMP-3(-) or MMP-3(+) groups. Percentages in (B)(D) indicate the 336 progression rates of joint destruction ( $\Delta mTSS > 0.5$ ) in the MMP-3(-) or MMP-3(+) group. 337

338

#### ROC analysis to determine the cutoff value of serum MMP-3 levels 339

340 Finally, the optimal serum MMP-3 cutoff value was examined from the ROC curve 341 using the Youden index. PSL-free female patients were selected because serum MMP-3 levels are affected by sex (the upper limits of the currently used reference range for male 342 343 and female are 121.0 and 59.7 ng/mL, respectively) and PSL; the study included a few male 344 patients. The ROC analysis revealed that the cutoff value of serum MMP-3 level was 49.7 345 ng/mL (area under the curve, 0.681; 95% Cl 0.560–0.802, and p < 0.01) (Fig. 5A) to achieve structural remission ( $\Delta mTSS < 0.5$ ). In patients with advanced joint destruction ( $\Delta mTSS \ge 0.5$ ), 346 347 few patients had serum MMP-3 levels <49.7 ng/mL (Fig. 5B). Therefore, in female patients with RA, lowering the serum MMP-3 level to <49.7 ng/mL is desirable to prevent the 348 progression of joint destruction. 349

350

351 Fig 5. ROC analysis to determine the cutoff value of serum MMP-3 levels. (A) The ROC analysis revealed the cutoff value of the serum MMP-3 was 49.7 ng/ml (area under the 352 353 curve: 0.681, 95%CI: 0.560–0.802, p < 0.01) to achieve ∆mTSS < 0.5. (B) In the group of patients with advanced joint destruction ( $\Delta mTSS \ge 0.5$ ), patients had serum MMP-3 levels 354

355 more than 49.7 ng/ml.

356

# 357 **DISCUSSION**

358	Progressive joint destruction is often observed during RA treatment, despite
359	negative CRP values [7]. The authors of a previous study proposed that residual MMP-3
360	activity is one of the responsible factors [17]. Our study showed a greater progression of
361	joint destruction in the MMP-3(+) group than in the MMP-3(-) group, despite arthritis being
362	well controlled by MTX therapy. This was evidenced by the negative CRP values and the
363	absence of swollen joints at 52 weeks. Furthermore, we found no correlation between CRP
364	and MMP-3 levels. These results suggest that persistently high serum MMP-3 levels lead to
365	joint destruction in patients with RA, including those in remission or with LDA.
366	During RA treatment, PSL administration is considered to provide a good
367	therapeutic effect when used in appropriate doses [6]; however, serum MMP-3 levels tend
368	to increase via an unknown mechanism [18, 19]. If this PSL-induced elevation of serum
369	MMP-3 is simply affected by the detection of serum MMP-3 in the clinical laboratory and is
370	not related to the pathophysiology of RA, joint destruction should progress more in the
371	PSL(-) group than in the PSL(+) group when their MMP-3 values are the same. However, our
372	results showed that the PSL-treated group had the same mean $\Delta$ mTSS and progression rates
373	of joint destruction as the PSL-free group. To exclude the possibility that PSL was
374	administered to patients with high disease activity, we investigated whether there was a
375	correlation between disease activity and PSL usage. We found no significant differences in

disease activity between the PSL (-) and PSL (+) groups. Furthermore, we observed no
correlation between the PSL dose and the serum MMP-3 level. These data suggest that the
PSL-induced increase in serum MMP-3 levels is also involved in the progression of joint
destruction. To the best of our knowledge, this is the first report to show that a PSL-induced
increase in serum MMP-3 levels is involved in joint destruction.

Interestingly, while we selected patients in remission or with LDA at baseline, the 381 382 MMP-3(+) group had significantly higher mean  $\Delta mTSS$  and progression rates of joint destruction than the MMP-3(-) group. Although it has been reported that joint destruction 383 is correlated with disease activity [20], our results suggest that serum MMP-3 values are 384 385 more important compared to DAS28-ESR and CDAI as an indicator of the radiographic 386 progression of joint destruction. There was no correlation between DAS28 and MMP-3 or 387 between CDAI and MMP-3 in patients with LDA or remission (data not shown). These results 388 also suggest that serum MMP-3 levels serve as an indicator of joint destruction, which implies that even with reduced inflammation and improved disease activity to LDA or 389 390 remission, joint destruction progression may still occur unless serum MMP-3 levels are 391 appropriately managed.

Previous studies have reported cutoff values for serum MMP-3 levels to prevent joint destruction [21,22]. These studies included RA patients with positive CRP values, high disease activity, and receiving PSL treatment. Furthermore, these studies calculated the cutoff value from a patient cohort comprising both sexes, despite different upper limit values of the reference range. In the present study, we analyzed the cutoff values for PSLfree female patients with RA, negative CRP values, and remission or LDA. In the ROC analysis,

398 the appropriate cutoff value of serum MMP-3 levels was found to be 49.7 ng/mL for 399 preventing the progression of joint destruction in female patients; this value falls below the 400 upper limit of the reference range (59.7 ng/mL). Serum MMP-3 levels may be a better 401 indicator of whether joint destruction is likely to progress and suggest treatment intensification, even if disease activity and CRP levels have remained low for up to 1 year. 402 403 The current reference range of serum MMP-3 was determined based on reference 404 individuals who met the following conditions: negative CRP values, negative RF values, normal fasting blood sugar levels, and normal liver enzyme test results. However, these 405 406 conditions do not exclude potential RA patients. Thus, it is not surprising that our cutoff value was lower than the upper limit of the reference range of serum MMP-3[23]. 407

408 MMP-3 can activate several other MMPs, including MMP-1, MMP-7, and MMP-9, 409 thereby increasing connective tissue matrix proteolysis [24]. It is thought that these 410 proteases contribute to joint destruction, either directly or indirectly, by degrading the cartilage extracellular matrix [9, 11]. Thus, it is difficult to achieve structural remission unless 411 412 serum MMP-3 levels are reduced to an appropriate level. However, there are currently no 413 therapeutic agents that directly lower serum MMP-3 levels. In our in vitro experiment, TNF-414 alpha-induced increase in MMP-3 levels from RA synoviocytes was inhibited by PSL (data not 415 shown); however, oral PSL administration increases serum MMP-3 levels in vivo [19]. In 416 order to develop new treatments that can decrease the serum MMP-3 levels to prevent joint 417 destruction in RA, it is necessary to elucidate the mechanism of the PSL-induced increase in 418 serum MMP-3 levels or develop new therapeutic agents that lower MMP-3 levels.

419

# 420 Limitations

421	This study has some limitations. The retrospective design limits the ability to draw
422	causal inferences. The sample size is relatively small, and the findings may not be
423	generalizable. The sample is predominantly from two university hospitals in the Kansai Area,
424	Japan, which may limit generalizability. The number of male patients was too small to
425	determine the adequate cutoff value of serum MMP-3 levels to prevent the progression of
426	joint destruction in males. Joint destruction lasting longer than 52 weeks was not estimated.
427	

# 428 Conclusion

Our study indicates that residual MMP-3 activity, regardless of PSL administration, may lead
to the progression of joint destruction in RA patients even after achieving clinical remission
or LDA through successful treatment with MTX. Intensification of therapy may be necessary
to achieve structural remission in female RA patients with serum MMP-3 levels of 49.7
ng/ml or higher.

### 434 **REFERENCES**

- 435 1. Koch AE (2007) The pathogenesis of rheumatoid arthritis. Am J Orthop (Belle Mead
- 436 NJ) 36:5–8
- 437 2. Smolen JS, Aletaha D, Bijlsma JWJ et al (2010) Treating rheumatoid arthritis to target:
- 438 Recommendations of an international task force. Ann Rheum Dis 69:631–637.
- 439 https://doi.org/10.1136/ard.2009.123919
- 440 3. Smolen JS, Breedveld FC, Burmester GR et al (2016) Treating rheumatoid arthritis to
- 441 target: 2014 update of the recommendations of an international task force. Ann

442 Rheum Dis 75:3–15. https://doi.org/10.1136/annrheumdis-2015-207524

- 443 4. Cronstein BN (2005) Low-dose methotrexate<sup>[]</sup>: A mainstay in the treatment of
- rheumatoid arthritis. Pharmacol Rev 57:15914465. https://doi.org/10.1124/pr.57.2.3
- 445 5. Pincus T, Yazici Y, Sokka T et al (2003) Methotrexate as the "anchor drug" for the
- 446 treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21:S179–S185
- 447 6. Smolen JS, Landewé RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the
- 448 management of rheumatoid arthritis with synthetic and biological disease-modifying
- 449 antirheumatic drugs: 2019 update. Ann Rheum Dis 79:S685–S699.
- 450 https://doi.org/10.1136/annrheumdis-2019-216655
- 451 7. Smolen JS, Van Der Heijde DMFM, St.Clair EW et al (2006) Predictors of joint damage
  452 in patients with early rheumatoid arthritis treated with high-dose methotrexate with
- 453 or without concomitant infliximab: Results from the ASPIRE trial. Arthritis Rheum

#### 454 54:702–710. https://doi.org/10.1002/art.21678

455	8.	Malemud CJ (2006) Matrix metalloproteinases (MMPs) in health and disease: An
456		overview. Front Biosci 11:1696–1701. https://doi.org/10.2741/1915
457	9.	Yasuo Y, Hiroyuki N, Ken'ichi O et al (2000) Matrix metalloproteinases and tissue
458		inhibitors ofmetalloproteinases in synovial fluids from patientswith rheumatoid
459		arthritis or osteoarthritis. Ann Rheum Dis 59:455–461.
460		https://doi.org/10.1136/ard.59.6.455
461	10.	Cawston T (1998) Matrix metalloproteinases and TIMPs: Properties and implications
462		for the rheumatic diseases. Mol Med Today 4:130–137.
463		https://doi.org/10.1016/S1357-4310(97)01192-1
464	11.	Okada Y (2000) Matrix-degrading metalloproteinases and their roles in joint
465		destruction. Mod Rheumatol 10:121–128. https://doi.org/10.3109/s101650070018
466	12.	Lerner A, Neidhöfer S, Reuter S, Matthias T (2018) MMP3 is a reliable marker for
467		disease activity, radiological monitoring, disease outcome predictability, and
468		therapeutic response in rheumatoid arthritis. Best Pract Res Clin Rheumatol 32:550-
469		562. https://doi.org/10.1016/j.berh.2019.01.006
470	13.	Kobayashi A, Naito S, Enomoto H et al (2007) Serum levels of matrix
471		metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis.
472		Arch Pathol Lab Med 131:563–570. https://doi.org/10.1043/1543-2165(2007)131
473	14.	Hattori Y, Kida D, Kaneko A (2019) Normal serum matrix metalloproteinase-3 levels

474		can be used to predict clinical remission and normal physical function in patients with
475		rheumatoid arthritis. Clin Rheumatol 38:181–187. https://doi.org/10.1007/s10067-
476		017-3829-9
477	15.	Yoshimi R, Hama M, Takase K et al (2013) Ultrasonography is a potent tool for the
478		prediction of progressive joint destruction during clinical remission of rheumatoid
479		arthritis. Mod Rheumatol 23:456–465. https://doi.org/10.1007/s10165-012-0690-1
480	16.	Bruynesteyn K, Boers M, Kostense P et al (2005) Deciding on progression of joint
481		damage in paired films of individual patients: Smallest detectable difference or
482		change. Ann Rheum Dis 64:179–182. https://doi.org/10.1136/ard.2003.018457
483	17.	Konishi H, Kanou SE, Yukimatsu R et al (2022) Adenosine inhibits TNF $lpha$ -induced MMP-
484		3 production in MH7A rheumatoid arthritis synoviocytes via A2A receptor signaling.
485		Sci Rep 12:1–9. https://doi.org/10.1038/s41598-022-10012-6
486	18.	Hattori Y, Kida D, Kaneko A (2018) Steroid therapy and renal dysfunction are
487		independently associated with serum levels of matrix metalloproteinase-3 in patients
488		with rheumatoid arthritis. Mod Rheumatol 28:242–248.
489		https://doi.org/10.1080/14397595.2017.1354431
490	19.	Ribbens C, Martin y Porras M, Franchimont N, Kaiser M, Jaspar J, Damas P, Houssiau
491		FMM (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic
492		diseases: Relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–
493		166. https://doi.org/10.1136/ard.61.2.161
494	20.	Tsuji H, Yano K, Furu M et al (2017) Time-averaged disease activity fits better joint

495	destruction in I	rheumatoid arthritis	s. Sci Rep 7:1–8. ł	https://doi.org	/10.1038/s41598
			-		, ,

#### 496 017-05581-w

- 497 21. Mamehara A, Sugimoto T, Sugiyama D et al (2010) Serum matrix metalloproteinase-3
- 498 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological
- disease modifying anti-rheumatic drugs. Kobe J Med Sci 56:98–107
- 500 22. Maksymowych WP, Landewé R, Conner-Spady B et al (2007) Serum matrix
- 501 metalloproteinase 3 is an independent predictor of structural damage progression in
- 502 patients with ankylosing spondylitis. Arthritis Rheum 56:1846–1853.
- 503 https://doi.org/10.1002/art.22589
- 504 23. Yumeto N, Yuko T, Satoshi N et al (2014) Basic study of reagents for measurement of
- 505 matrix metalloproteinase-3. Igakukensa 63:579–585.
- 506 https://doi.org/10.1007/s12291-010-0025-y
- 507 24. Ogata Y, Enghild JJ, Nagase H (1992) Matrix metalloproteinase 3 (stromelysin)
- 508 activates the precursor for the human matrix metalloproteinase 9. J Biol Chem
- 509 267:3581–3584. https://doi.org/10.1016/S0021-9258(19)50563-4
- 510